UREX Drug Patent Profile
Which patents cover Urex, and what generic alternatives are available?
Urex is a drug marketed by Quagen and is included in one NDA.
The generic ingredient in UREX is methenamine hippurate. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the methenamine hippurate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Urex
A generic version of UREX was approved as methenamine hippurate by AUROBINDO PHARMA LTD on July 5th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for UREX?
- What are the global sales for UREX?
- What is Average Wholesale Price for UREX?
Summary for UREX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 60 |
| Patent Applications: | 2,230 |
| DailyMed Link: | UREX at DailyMed |
US Patents and Regulatory Information for UREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quagen | UREX | methenamine hippurate | TABLET;ORAL | 016151-001 | Approved Prior to Jan 1, 1982 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
